ArticleOncotarget2025

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma.

Leonardo Gomes da Fonseca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.